Overview of Neurazine

Quick Facts

Property	Description
Active ingredient	Chlorpromazine hydrochloride
Forms	Tablets, Oral solution, Injectable solution (Ampoules)
Pharmacological class	Typical Antipsychotic (Neuroleptic)
General purpose	Chemical stabilization of severe mental and emotional distress
Origin	Synthetic, Phenothiazine derivative

What Type of Medicine is Neurazine (Chlorpromazine)?

Neurazine is a trade name for the active compound Chlorpromazine, a synthetic agent classified as a typical antipsychotic, which is a type of neuroleptic medication. It functions as a psychotropic agent intended for the high-level management of severe disturbances in thought, mood, and perception by chemically modulating the central nervous system. Chlorpromazine is recognized globally as the foundational member of the entire class of first-generation antipsychotics (FGAs), with its introduction marking a major advance in psychiatric care. Its established role in managing psychotic illnesses is recognized through decades of clinical use and comprehensive reviews. This enduring medical recognition reflects its utility in stabilizing patients experiencing acute agitation or profound psychological distress.

Composition and Forms of Chlorpromazine

The medicine is a single-ingredient product derived from the phenothiazine chemical family, typically formulated using Chlorpromazine hydrochloride as the active substance. The drug’s position as a classic, widely used agent means its active ingredient is manufactured and distributed under numerous global brands, including Largactil and Thorazine. For patient care flexibility, Chlorpromazine is available in several physical forms: as tablets and an oral solution for routine dosing (oral route), and as an injectable solution (ampoules) for acute situations that require rapid intervention via intramuscular or intravenous administration. Furthermore, Chlorpromazine possesses strong antiemetic properties, contributing to its use in relieving severe, unrelenting nausea and vomiting.

What side effects are possible with Neurazine?

Possible Side Effects and Safety Information

The safety profile of Neurazine (Chlorpromazine) is formally classified by regulatory bodies based on the frequency and the affected System-Organ Class (SOC). Adverse reactions commonly involve the Nervous System (e.g., sedation, drowsiness, and various Extrapyramidal Symptoms (EPS) like acute dystonia and parkinsonism), the Vascular System (e.g., postural hypotension), and the Endocrine/Metabolic System (e.g., weight gain, hyperprolactinemia).

Regulatory Classification of Serious Adverse Reactions

The official labeling highlights several serious adverse reactions, though they may occur infrequently. These include potentially fatal conditions such as Neuroleptic Malignant Syndrome (NMS), a rare but severe symptom complex. Long-term exposure is associated with the risk of Tardive Dyskinesia (TD), characterized by involuntary movements. Hematologic safety concerns, such as Agranulocytosis (a severe reduction in white blood cells), are also officially documented, typically presenting between the fourth and tenth week of treatment. The drug's effect on heart rhythm, particularly QT interval prolongation, carries a documented risk of serious cardiac events, including Sudden Cardiac Death.

Safety Patterns and Special Populations

Safety notes specify that certain effects, like acute dystonia, are more frequent during the first four days of treatment or following a dose adjustment, while Parkinsonism generally appears later. Specific safety statements exist for vulnerable groups: older adults with dementia-related psychosis have a documented increased risk of death associated with antipsychotic use. Neonates exposed during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. The label also advises caution regarding the impairment of physical and mental abilities, especially at the start of therapy.

Overdose and Emergency Response

️ Neurazine Overdose and When to Seek Help

Taking more than the prescribed dose of Neurazine (a common name for the antipsychotic drug chlorpromazine) can lead to a serious medical emergency. Overdose symptoms are often related to excessive central nervous system depression and cardiovascular effects.

Key symptoms of a Neurazine overdose may include severe drowsiness progressing to loss of consciousness or coma, seizures (convulsions), and uncontrollable muscle movements of the face or body. Cardiovascular effects can manifest as severe hypotension (very low blood pressure) and cardiac arrhythmias, such as prolongation of the QT interval, which are life-threatening.

When to Seek Emergency Medical Help

Immediate medical intervention is essential for a suspected Neurazine overdose. Call emergency services immediately if the individual:

Is unresponsive or cannot be awakened (coma).
Has difficulty breathing or has stopped breathing.
Is experiencing a seizure.
Has a fast, irregular, or pounding heartbeat.
Exhibits severe dizziness or fainting (indicating dangerously low blood pressure).

There is no specific antidote for Neurazine overdose. Treatment involves supportive measures, including maintaining an open airway, managing blood pressure with intravenous fluids and vasopressors, and continuous monitoring of cardiac function. Activated charcoal may be administered in the emergency setting if ingestion was recent.

Therapeutic Uses of Neurazine

What Neurazine Treats: Main Uses and Benefits

Neurazine (Chlorpromazine) is commonly used across several crucial therapeutic domains for managing severe symptom patterns and acute episodes, offering support and stabilization when symptoms become overwhelming. This medication is utilized for its role in both mental health and specific physical conditions.

This medicine is generally applied to conditions like schizophrenia, the manic phase of bipolar disorder, and for severe behavioral problems in children. Outside of mental health, it is relevant for addressing intense physical symptoms such as severe, unrelenting nausea and vomiting, intractable hiccups, and severe muscle spasms associated with tetanus. This range of use means that it is often utilized to manage symptom clusters that may become intense or disruptive, helping patients cope more steadily with difficult episodes.

“Applied in clinical settings that involve acute or unstable symptom patterns, it is considered relevant for supportive management during phases of heightened patient distress.”

Quick Fact: Relief for Refractory Symptoms

Symptom Domain	Key Symptom Cluster	Patient Benefit
Psychotic	Hallucinations, Delusions, Agitation	Easing of acute psychological distress
Gastrointestinal	Severe, Unrelenting Nausea and Vomiting	Improved comfort during physical discomfort
Neurological	Intractable Hiccups, Severe Muscle Spasms	Managing persistent, disruptive manifestations

This medication supports the overall easing of acute psychological distress by addressing the pronounced symptoms of thought disorders, and may assist with managing heightened physiological activity in behavioral contexts. In non-psychiatric contexts, it contributes to improved comfort during periods of heightened physical discomfort when symptoms are unresponsive to other approaches.

Regulatory References

NIH StatPearls overview

Eligibility and Restrictions for Use

Population Eligibility for Neurazine (Chlorpromazine)

The ability to use Neurazine (Chlorpromazine) is strictly defined by regulatory guidelines based on patient status, age, and existing health conditions.

Absolute Contraindications

Neurazine must not be used in patients with known hypersensitivity to phenothiazines or Chlorpromazine. Use is prohibited in patients who are in comatose states or severe CNS depression, or who have severe cardiovascular disease, circulatory collapse, or a history of blood dyscrasias. The medicine is also strictly contraindicated for nursing mothers (lactation).

Eligibility by Age and Population

Population Group	Official Regulatory Status
Adults & Children ge 6 months	Use is established for specific labeled indications.
Infants lt 6 months	Safety and dosage not established; generally not recommended.
Older Adults	Requires reduced dosage and close observation.

Conditional Restrictions

The medicine is not approved for elderly patients with dementia-related psychosis, as this carries an increased mortality risk. Close monitoring and potential dosage reduction are required for patients with hepatic or renal impairment or those with epilepsy. Use during pregnancy is generally not recommended unless judged essential.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Neurazine (Chlorpromazine) is primarily structured around two critical categories of interactions: pharmacodynamic effects and pharmacokinetic effects involving the body's enzyme systems.

Central Nervous System (CNS) Depressants such as alcohol, opioids, and benzodiazepines, can have an additive effect when combined with Neurazine, significantly increasing the risk of profound sedation, respiratory depression, and severely low blood pressure. Due to this pharmacodynamic synergy, co-administration is often restricted or avoided.

QT-Prolonging Agents (e.g., certain anti-arrhythmics or antipsychotics) present a severe interaction risk. Neurazine itself can prolong the QT interval, and combining it with other agents that share this property creates an additive effect, increasing the potential for serious heart rhythm disturbances.

Neurazine is a substrate and inhibitor of the Cytochrome P450 (CYP) enzyme system, notably CYP2D6. Co-administering strong CYP2D6 inhibitors (e.g., fluoxetine) can increase Neurazine levels in the body. Conversely, Neurazine can inhibit the metabolism of other drugs cleared by CYP2D6, necessitating monitoring or dose adjustment for the co-administered drug. Other interactions include reduced absorption when taken with antacids or anticholinergic drugs, and antagonism of effects when combined with Levodopa or certain antidiabetic agents.

Mechanism of Action

Neurazine is a tricyclic phenothiazine that acts as a non-selective receptor antagonist within the central nervous system. Its primary molecular target is the D2 dopamine receptor, where it exerts a blocking effect, inhibiting the binding of endogenous dopamine, particularly in subcortical pathways like the mesocortical and mesolimbic systems. The blockade of D2 receptors initiates a compensatory feedback loop, initially increasing neuronal dopamine release; however, chronic antagonism ultimately leads to a down-regulation of dopamine production and a decrease in dopaminergic neural activity. Additionally, Neurazine interacts with and blocks multiple other G-protein coupled receptors, including serotonin receptors (5-HT1A, 5-HT2A), histamine H1 receptors, muscarinic acetylcholine receptors (M1, M2), and various alpha-adrenergic receptors. These diverse molecular interactions modulate several intracellular signaling cascades, contributing to widespread system-level physiological consequences such as alterations in vasomotor tone, hypothalamic-pituitary axis regulation, autonomic nervous system outflow, and core thermoregulation.

Dosage and Administration Information

How to Use Neurazine: Standard Administration Guidelines

The use of Neurazine follows established protocols. These instructions detail the formats, routes, and specific requirements for administration to facilitate proper use.

Standard Administration Scope

Field	Content
Route of Administration	Oral (Film-Coated Tablets, Oral Solution) and Intravenous (IV) Infusion.
Standard Dosing Schedule	Adult starting dose is 200 mg once daily. The adult maintenance dose ranges from 400 mg to 800 mg daily, administered in two divided doses. Pediatric dosing is based on body weight (10 mg/kg/day), not to exceed the adult maximum dose.
Timing in Relation to Meals	May be taken without regard to meals (with or without food).

Preparation and Special Conditions

Neurazine requires specific procedural steps for administration:

Oral Tablets: Must be swallowed whole. Tablets are not to be crushed, broken, or chewed.
IV Infusion: The 10 mg/mL solution must be diluted prior to administration using 100 mL of 0.9% Sodium Chloride or 5% Dextrose. The resulting infusion must be administered slowly over a period of at least 60 minutes.
Population Adjustments: For Geriatric Patients (age 65 and older) and those with renal impairment, a reduced starting dose of 100 mg once daily is utilized, with the maximum dose for renal impairment not to exceed 400 mg.

This protocol defines the procedures for drug intake, including required dilution steps and specific parameters for administration rate and tablet handling.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Neurazine

This overview provides a factual summary of the formal research that informed the regulatory status of Chlorpromazine (Neurazine). It focuses strictly on the types of studies conducted, what outcomes were measured, and where scientific certainty remains low. This information is purely descriptive and does not offer any medical or treatment advice.

Evidence Base for Schizophrenia and Psychotic Disorders

The evidence base for Chlorpromazine in conditions like schizophrenia is founded on numerous studies across decades, including extensive Randomized Controlled Trials (RCTs), Systematic Reviews, and Meta-analyses. Research explored how symptoms change over time in adults diagnosed with schizophrenia, focusing on outcomes related to symptom intensity, daily functioning, and the frequency of psychotic episodes.

Research examined patterns observed in the studies related to changes in acute psychotic symptoms. Research highlights changes measured during the study period, such as rates of relapse frequency and discontinuation. The overall data contributed to its inclusion as a historical context for the study of these conditions.

Evidence for Non-Psychiatric Indications

This part details the research conducted for uses outside of mental health, describing the evidence structure that was studied for research exploring severe physical symptoms. The use of Chlorpromazine for severe, unrelenting nausea and vomiting was evaluated in early clinical evaluations and established regulatory data. Studies monitored outcomes related to physical discomfort in a general patient population, including children aged 6 months and older. Research describes its evaluation in patients whose symptoms are often reported as unresponsive to other approaches.

Research Structure for Rare Symptoms (Hiccups, Tetanus, Porphyria)

For rare conditions like intractable hiccups, tetanus, and acute intermittent porphyria, the evidence structure relies mainly on case reports and case series rather than large, controlled trials. Studies observed outcomes related to systemic or functional imbalance. Clinical documentation reports patterns related to the change measured in symptoms in highly specific patient groups. The evidence quality varies across these studies, and the certainty remains low compared to the high-grade evidence for psychotic disorders.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Neurazine (FAQ)

Q: Can Neurazine affect my sleep?

Official information notes side effects involving the nervous system. These may include feelings of drowsiness or sedation, as well as reports of difficulty falling asleep or staying asleep. This is one of the effects noted in regulatory documents, especially when treatment begins.

Q: Is Neurazine habit-forming or addictive?

According to regulatory classification in the United States, this medicine is not considered a controlled substance. This means it has a DEA Schedule of None.

Q: What are the typical withdrawal symptoms mentioned for Neurazine?

Regulatory documents state that suddenly stopping this medicine may result in certain withdrawal symptoms. These symptoms can include nausea, vomiting, stomach pain, dizziness, and shakiness. Information on stopping the medicine, or any required changes in use, is subject to the guidance of a healthcare professional.

Q: Can Neurazine cause changes in mood or behavior?

This medicine is approved for treating certain behavior problems and psychotic disorders. Separately, side effects may include changes such as feeling agitation, nervousness, or restlessness. Unexpected changes are noted in the official guidance, and reporting these to a healthcare professional is consistent with label instructions.

Q: Does Neurazine interact with herbal remedies or vitamins?

The official labeling advises informing the healthcare provider about all substances being taken. This includes all prescription and over-the-counter (OTC) medicines, vitamins, minerals, herbal products, and other supplements to check for potential interactions.

Q: What kind of monitoring is needed when taking Neurazine?

For patients on long-term or high-dose therapy, regulatory documents suggest the need for periodic ocular examinations to check for potential changes in the eye. Additionally, monitoring is advised for a range of potential adverse effects associated with this class of medication.

Q: When is the best time of day to take Neurazine?

Official administration guidelines state that the medicine may be taken without regard to meals. However, regulatory documents also note that the medicine may impair mental and/or physical abilities, particularly during the initial days of therapy. The potential for drowsiness may be considered when determining the administration time.

Q: What are the most common reasons doctors prescribe Neurazine?

Official indications for this medicine list its use for the management of psychotic disorders, the control of severe nausea and vomiting, and the relief of intractable hiccups. These uses are confirmed by the regulatory approval documents.

Q: Are there any foods or drinks I should avoid while taking Neurazine?

Official labeling strongly advises that alcohol should be avoided due to the risk of additive sedation and severely low blood pressure. Otherwise, regulatory documents state there are no known interactions with common foods or non-alcoholic drinks.

Q: How long do most people take Neurazine for?

Regulatory documents discuss the potential for risks associated with long-term use, defining 'prolonged periods' as typically 2 to 3 years or more in certain patient populations. The determination of the overall duration of therapy is a clinical decision based on the treated condition.

Q: Can Neurazine cause mental fog or difficulty concentrating?

Official labeling states the medicine may impair mental and/or physical abilities, especially at the start of therapy. Official labeling cautions that the impairment of these abilities may require attention when performing tasks that require full concentration.

Q: What kind of studies have been done on Neurazine?

The medicine's long-established regulatory status is informed by studies across decades. This evidence base includes extensive Randomized Controlled Trials (RCTs) and systematic reviews for major indications, alongside clinical evaluations and case reports for other approved uses.

Q: Can I drive a car while taking Neurazine?

Regulatory documents caution against activities requiring alertness such as operating vehicles or machinery. This warning is due to the potential for the medicine to impair physical and mental abilities, especially when treatment begins.

Q: Why do some people feel sleepy after taking Neurazine?

The side effect of sedation or drowsiness is expected due to the medicine's action on specific receptors in the brain. Pharmacological data indicates that this effect is linked to the medicine's function as a blocker of histamine H1 receptors.

Q: What should I do if a side effect is bothering me?

Official guidance describes checking with a healthcare professional as the appropriate procedural step if side effects continue or are bothersome over time. For serious or severe symptoms, official instructions indicate that immediate contact with a doctor is necessary.

Q: Are there different strengths or doses of Neurazine available?

Yes, the medicine is available in several regulatory-approved forms. These include an oral solution, an injectable solution, and oral tablets offered in various strengths, such as 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg.

Q: Why is Neurazine sometimes prescribed for conditions other than the main one?

Regulatory documents confirm that the medicine has multiple approved uses beyond mental health conditions. These include treating severe nausea and vomiting, intractable hiccups, and acute intermittent porphyria, which are listed as official indications for the drug.

Q: What is the half-life of Neurazine?

Authoritative pharmacokinetic data indicates that the amount of the parent drug in the body decreases by half over a period defined as its half-life. For this medicine, the half-life is described as being between 23 and 37 hours.

Q: Is Neurazine a scheduled substance?

The medicine is classified by the US Drug Enforcement Administration (DEA) as having no scheduled status. This means it is not designated as a controlled substance for its potential for dependence or misuse.

Q: Why do official documents mention that Neurazine's use should be reviewed regularly?

Official documents advise a regular review and observation due to specific risks related to long-term use. This includes advising periodic ocular examinations to check for potential changes like lens opacities and abnormal skin pigmentation.

How should Neurazine be stored and disposed of?

Storage and Disposal Requirements for Neurazine

The storage of Neurazine (Chlorpromazine) must adhere strictly to environmental controls specified in official regulatory labeling to maintain stability.

Storage Conditions

Requirement	Specifics Based on Regulatory Labeling
Temperature	Store at controlled room temperature, 20^circC to 25^circC (68^circF to 77^circF), with allowed brief excursions up to 30^circC (86^circF).
Protection	Protect from light and moisture. Liquid forms, such as the solution, must not be frozen.
Container	Keep the medicine in its original, tight, light-resistant container.
Safety	The medication must be kept out of the sight and reach of children.

Disposal

Unused or expired Neurazine must be disposed of in accordance with local regulations, often through authorized take-back programs. General regulatory guidance advises against flushing the product down a toilet or pouring it into a drain.

Neurazine